Further research in vivo and clinical studies are warranted to validate the efficacy and safety of PDIA3 inhibition in combination with TMZ, with the ultimate goal of improving patient outcomes in the WHO grade IV gliomas. Here, PDIA3 is linked to central nervous system cancer.